Advanced SearchNewsfeedFollowed Companies

Cardiff Oncology's Competitors, Revenue, Number of Employees, Funding and Acquisitions

Trovagene develops drug-based therapeutics that target cell division for the treatment of leukemias, lymphomas, and soli... Read more

Based on data from Cardiff Oncology's latest SEC filings

Annual Revenue

Based on data from Cardiff Oncology's latest SEC filings

Employees

CEO Avatar

CEO

- -

CEO Approval Rating

- -/100

OVERVIEW

Founded:

- -

Headquarters:

San Diego, California
San Diego County

Status:

PublicNASDAQCRDF

Industry Sector:

Biotechnology

SIC Code:

2836NAICS listing »

Top Competitors or Alternatives

Missing a competitor? Contribute!

Weigh-in!

Help the Owler community know more

Competitor - 1/1

Is Genecast a competitor of Cardiff Oncology?

I don't know

Trending News for Cardiff Oncology and Cardiff Oncology's Competitors

June 1, 2020

PharmiWeb

INOVIO's COVID-19 DNA Vaccine INO-4800 Demonstrates Robust Neutralizing Antibody and T Cell Immune Responses in Preclinical Models

PLYMOUTH MEETING, Pa., May 20, 2020 /PRNewswire/ -- INOVIO (NASDAQ:INO) today announced the publicati... See more »

June 1, 2020

St Louis Post Dispatch

GeneNews: 1Q Earnings Snapshot

RICHMOND HILL, Ontario (AP) - GeneNews Ltd. (GNWSF) on Monday reported a loss of $2.7 million in its ... See more »

June 2, 2020

Ambry Blog

Hereditary Cancer Testing Menu Update

rss feeds... See more »

Competitive Analysis

TOP COMPETITORS OR ALTERNATIVES

bluebird bio is Cardiff Oncology's biggest rival. bluebird bio was founded in 1992, and is headquartered in Cambridge, Massachusetts. Like Cardiff Oncology, bluebird bio also works within the Biotechnology sector. bluebird bio generates $53.6M more revenue vs. Cardiff Oncology.

Inovio is one of Cardiff Oncology's top competitors. Inovio's headquarters is in Plymouth Meeting, Pennsylvania, and was founded in 1979. Like Cardiff Oncology, Inovio also works within the Biotechnology sector. Inovio generates 621% of Cardiff Oncology's revenue.

RANK

COMPANY

LEADERSHIP

CEO SCORE

EMPLOYEES

TOTAL FUNDING

REVENUE

CEO

- -
12
$50M
$ < 1M
1

Nick Leschly

President & CEO

79/100
764
$275.9M
$44.7M
2

J. Joseph Kim

President & CEO

72/100
281
$296.4M
$2.6M
3

Du Bo

Co-Founder & CEO

90/100
500
$94M
$3M
4

CEO

- -
829
$90.2M
$441.9M
5

Victor Shi

Co-Founder & CEO

82/100
3
$11M
$ < 1M
6

Joe Victor

President & CEO

85/100
49
$57M
$3M
7

James R Howard-Tripp

Chairman & CEO

86/100
61,300
$22.9M
$4.5B
8

Dan Snyder

President & CEO

79/100
125
$19.1M
$10M
9

Cindy Perettie

CEO

79/100
535
$165.5M
$541.1M
The top 10 competitors in Cardiff Oncology's competitive set are bluebird bio, Inovio, Arcellx, Genecast, Genomic Health, NuProbe, Rarecyte, GeneNews, MolecularMD and Foundation Medicine. Together they have raised over 1.0B between their estimated 3.9K employees. Cardiff Oncology has 12 employees and is ranked 10th among it's top 10 competitors. The top 10 competitors average 5,856.

Quarterly and Annual Revenue

Trailing 12-Months Trend (TTM)

Annual Revenue

$ < 1M

Cardiff Oncology's revenue is the ranked lowest among it's top 10 competitors. The top 10 competitors average 504.2M. Over the last four quarters, Cardiff Oncology's revenue has decreased by 51%. Specifically, in Q1 2020's revenue was $ < 1M; in Q4 2019, it was $ < 1M; in Q3 2019, it was $ < 1M; in Q2 2019, Cardiff Oncology's revenue was $ < 1M.

Acquisitions

No recent acquisitions found related to Cardiff Oncology

Cardiff Oncology Funding History

Cardiff Oncology has participated in 8 rounds of funding. In total Cardiff Oncology has raised $50.0M. Cardiff Oncology's last funding round was on Oct 2019 for a total of $5.0M

ROUND

FUNDING DATE

AMOUNT

INVESTORS

Equity
Oct 2019
$5M
-
Equity
Aug 2019
$1.5M
-
Equity
May 2019
$1.5M
-
Equity
Apr 2019
$1.5M
-
Private Placement
Jul 2017
$7.1M
-

Total Funding: $50M

Cardiff Oncology has participated in 8 rounds of funding. In total Cardiff Oncology has raised $50.0M. Cardiff Oncology's last funding round was on Oct 2019 for a total of $5.0M

Investments

No recent investments found related to Cardiff Oncology

Cardiff Oncology News

April 8, 2020MARKETEXCLUSIVE

Trovagene, Inc. (NASDAQ:TROV) Files An 8-K Other Events

On April 8, 2020, Trovagene, Inc. (the “Company”) issued a press release announcing announced it will... See more »
March 5, 2020Market Exclusive

Trovagene, Inc. (NASDAQ:TROV) Files An 8-K Other Events

Trovagene, Inc. (the “Company”) issued a press release announcing the nomination of three new board m... See more »
February 5, 2020Market Exclusive

Trovagene, Inc. (NASDAQ:TROV) Files An 8-K Other Events

On February 5, 2020, Trovagene, Inc. issued a press release announcing that a poster featuring effica... See more »
January 29, 2020MedCity News

Trovagene tries roundabout approach to colorectal cancer with 'undruggable' mutation

Although they're still early, the company presented Phase Ib/II study data showing its PLK1 inhibitor... See more »
January 29, 2020Pharmabiz

Trovagene announces positive data from phase 1b/2 trial of onvansertib plus FOLFIRI & Avastin for second─line treatment of KRAS─mutated mCRC

Trovagene, Inc, a clinical─stage, oncology therapeutics company targeting cancers that are both highl... See more »
January 29, 2020firstwordpharma

Trovagene Receives Approximately $1.45 Million From Exercise of Warrants

Trovagene, Inc. (Nasdaq: TROV),a clinical-stage, Precision Cancer Medicine™ oncology therapeutics com... See more »
January 22, 2020FinanzNachrichten

First Drug For TED Secures Approval, TROV On Watch, EVOK Faces FDA In June

LONDON (dpa-AFX) - Today's Daily Dose brings you news about the update on Evoke Pharma's resubmitted ... See more »

Cardiff Oncology Press Releases

February 13, 2020PR Newswire

Trovagene Presents Phase 2 Data Demonstrating the Ability of Onvansertib to Overcome Zytiga®-Resistance and Provide Clinical Benefit for mCRPC Patients

SAN DIEGO, Feb. 13, 2020 /PRNewswire/ -- Trovagene, Inc. (Nasdaq: TROV), a clinical-stage, oncology t... See more »
November 14, 2019PR Newswire

Trovagene Presents Positive Data in Metastatic Prostate Cancer Phase 2 Trial Showing Clinical Response in Patients Resistant to Zytiga®

SAN DIEGO, Nov.14, 2019 /PRNewswire/ -- Trovagene, Inc. (Nasdaq: TROV), a clinical-stage, Precision C... See more »
November 7, 2019PR Newswire

Trovagene Announces Third Quarter 2019 Results and Highlights

SAN DIEGO, Nov. 7, 2019 /PRNewswire/ -- Trovagene, Inc. (Nasdaq: TROV), a clinical-stage, Precision C... See more »
October 22, 2019LD Micro

Trovagene Announces Positive Response to Treatment in Phase 1b/2 Trial of Onvansertib in Patients with KRAS-Mutated Metastatic Colorectal Cancer

Read this press release and other recent news about TrovaGene Inc. (TROV) at ldmicro.com... See more »
July 22, 2019streetinsider

ESMO Accepts Trovagene AML Clinical Trial Abstract for Oral Presentation

SAN DIEGO, July 22, 2019 /PRNewswire/ -- Trovagene, Inc. (Nasdaq: TROV), a clinical-stage, Precision ... See more »
May 7, 2019StreetInsider

Trovagene Announces First Quarter 2019 Results and Highlights

Trovagene, Inc. (Nasdaq: TROV), a clinical-stage oncology therapeutics company, using a precision med... See more »
April 5, 2019StreetInsider

Trovagene Announces $1.5 Million Equity Investment at Premium to Market from Institutional Investor, Lincoln Park Capital

Trovagene, Inc. (Nasdaq: TROV), a clinical-stage oncology therapeutics company, using a precision med... See more »

Cardiff Oncology Videos

July 5, 2016Trovagene Vimeo Channel

"How Liquid Biopsies Have Revolutionized the Cancer Space" on VIMEO

Cast: Trovagene... See more »
June 20, 2016Trovagene Vimeo Channel

"Trovagene/Trovera B-Roll Video" on VIMEO

B-Roll video from booth.Cast: Trovagene... See more »
June 14, 2016Trovagene Vimeo Channel

"The Power of Trovera in Detecting EGFR T790M Mutations in Non-Small Cell Lung Cancer" on VIMEO

Cast: Trovagene... See more »
June 14, 2016Trovagene Vimeo Channel

"What Makes Trovagene's Technology Unique?" on VIMEO

Cast: Trovagene... See more »
June 2, 2016Trovagene Vimeo Channel

"Trovera Case Study" on VIMEO

Cast: Trovagene... See more »
November 16, 2015TROVAGENE VIMEO CHANNEL

"Trovagene Sample Collection Instructions for Healthcare Providers" on VIMEO

This video shows the simple steps for collecting and shipping a urine sample to our lab for processin... See more »
June 19, 2015TROVAGENE VIMEO CHANNEL

"Trovagene and ECD Global Alliance: Monitoring BRAF Mutations with Urine Based Liquid Biopsy" on VIMEO

Cast: Trovagene... See more »

Social Statistics

Headquarters

11055 Flintkote Avenue

San Diego, California92121

1-858-952-7570

Driving Directions »

Trending Companies

Summary

ABOUT

Overview

Trovagene develops drug-based therapeutics that target cell division for the treatment of leukemias, lymphomas, and solid tumor cancers.Cardiff Oncology's headquarters is located in San Diego, California, USA 92121. It has raised 50.0M in 8 rounds. Th...

Website

trovageneoncology.com

Frequently Asked Questions about Cardiff Oncology

  1. How much revenue does Cardiff Oncology generate?

    Cardiff Oncology generates $ < 1M in revenue

  2. How much funding does Cardiff Oncology have?

    Cardiff Oncology has historically raised $50M in funding

  3. Where is Cardiff Oncology's headquarters?

    Cardiff Oncology's headquarters is in San Diego California, USA

  1. How many employees does Cardiff Oncology have?

    Cardiff Oncology has 12 employees

  2. What sector does Cardiff Oncology operate in?

    Cardiff Oncology is in Biotechnology

  3. Who are Cardiff Oncology's competitors?

    Cardiff Oncology's top competitors are bluebird bio, Inovio, Arcellx
Stay up-to-date with the latest news on Cardiff Oncology